Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Giuseppina Ruggeri is active.

Publication


Featured researches published by Giuseppina Ruggeri.


Clinica Chimica Acta | 2011

HE4 and epithelial ovarian cancer: Comparison and clinical evaluation of two immunoassays and a combination algorithm☆

Giuseppina Ruggeri; Elisabetta Bandiera; Laura Zanotti; Silvana Belloli; Antonella Ravaggi; Chiara Romani; Eliana Bignotti; Renata A. Tassi; Germana Tognon; Claudio Galli; Luigi Caimi; Sergio Pecorelli

BACKGROUND Two commercial immunoassays for HE4 have been compared and the diagnostic accuracy of HE4, CA 125 and the combinatory ROMA algorithm for epithelial ovarian cancer (EOC) has been evaluated. METHODS HE4 and CA125 were measured on sera obtained from 259 women (73 healthy, 90 with benign ovarian or adnexal diseases, 96 with EOC). The ARCHITECT CMIA HE4 assay was compared with the Fujirebio EIA HE4, and the risk for EOC by the combinatory ROMA algorithm (HE4+CA 125) was assessed with both HE4 assays. RESULTS The CMIA HE4 assay showed a good linearity (r>0.9998) and precision (interassay and total CVs <4%). The correlation with EIA HE4 was linear (r=0.994), with an average bias of 0.4%. By ROC curve analysis, the sensitivity for EOC at a fixed specificity of 90%, 95% and 99% was 89.6%, 84.4% and 79.2% by CMIA HE4, 84.4%, 83.3% and 79.2% by EIA HE4, 86.5%, 76.0% and 59.4% by CMIA CA125. The accuracy of the ROMA algorithm determined by CMIA or EIA HE4 was very similar (AUC 87.1% vs. 87.6%; p=n.s.) and greater in menopause. CONCLUSIONS The two HE4 assays showed a good correlation and similar clinical value, with a greater precision for CMIA. HE4 was more specific and accurate than CA125, supporting its use in addition to clinical and imaging criteria for the discrimination of benign from malignant ovarian lesions. The ROMA algorithm showed a good accuracy for discriminating women at high risk for EOC.


Clinical Chemistry and Laboratory Medicine | 2012

Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome.

Laura Zanotti; Eliana Bignotti; Stefano Calza; Elisabetta Bandiera; Giuseppina Ruggeri; Claudio Galli; Germana Tognon; Monica Ragnoli; Chiara Romani; Renata A. Tassi; Luigi Caimi; Franco Odicino; Enrico Sartori; Sergio Pecorelli; Antonella Ravaggi

Abstract Background: The purpose of this study was to assess the diagnostic and prognostic impact of preoperative serum determination of human epididymis protein 4 (sHE4), and to investigate its potential correlation with clinicopathological features and survival endpoints in endometrial cancer patients. Methods: Preoperative serum samples from 193 endometrial cancer patients and 125 women with normal endometrium were measured for sHE4 and serum CA125 (sCA125) concentrations by quantitative chemiluminescent microparticle immunoassays on the automated Architect instrument. Results: sHE4 concentrations were significantly higher in endometrial cancer patients regardless of tumour stage and grade compared with normal controls. Setting the specificity at 95%, the sensitivities in detecting endometrial cancer patients were 66% for HE4, 33% for CA125 and 64% for the combination of the two markers. High concentrations of both HE4 and CA125 significantly correlated with all clinicopathological features characterising a more aggressive tumour phenotype. In multivariate analysis, only high preoperative sHE4 concentrations, but not sCA125, were independent prognostic factors for shorter Overall Survival, Disease-Free Survival and Progression-Free Survival. Conclusions: HE4 is more sensitive and specific than CA125 in distinguishing endometrial cancer patients from women with normal endometrium, regardless of tumour stage and grade. sHE4 appears to be associated with a more aggressive tumour variant and it could be clinically useful, in identifying high-risk endometrial cancer patients, for a tailored surgical and postoperative therapy. HE4 significant correlation with decreased Overall Survival, Disease Free Survival and Progression Free Survival suggests its potential role as a novel prognostic marker for endometrial cancer.


Journal of Hypertension | 2014

Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension.

Carolina De Ciuceis; Massimo Salvetti; Claudia Rossini; Maria Lorenza Muiesan; Anna Paini; Sarah Duse; Elisa La Boria; Francesco Semeraro; Anna Cancarini; Claudia Agabiti Rosei; Annamaria Sarkar; Giuseppina Ruggeri; Luigi Caimi; Doris Ricotta; Damiano Rizzoni; Enrico Agabiti Rosei

Background: It has been previously demonstrated that dihydropyridine calcium channel blockers may possess antioxidant properties and might improve vascular structure. Combination treatment with an angiotensin-converting enzyme inhibitor may have additional advantages, compared with a thiazide diuretic, in this regard. The aim of the present study was, therefore, to investigate the effects of a short-term treatment with lercanidipine, and to compare two combination treatments: lercanidipine + enalapril vs. lercanidipine + hydrochlorothiazide on structural alterations in retinal arterioles, on skin capillary density and on large artery distensibility. Patients and methods: Twenty essential hypertensive patients were included in the study and treated for 4 weeks with lercanidipine 20 mg per day orally. Then they were treated for 6 months with lercanidipine + enalapril (n = 10) or lercanidipine + hydrochlorothiazide (n = 10) combinations. Investigations were performed in basal condition, after appropriate washout of previous treatments, after 4 weeks of lercanidipine monotherapy treatment, and at the end of the combination treatment. Non-invasive measurements of wall-to-lumen ratio (W/L) and other morphological parameters of retinal arterioles using scanning laser Doppler flowmetry were performed (Heidelberg Retina Flowmeter, Heidelberg Engineering). Capillary density was evaluated by capillaroscopy, whereas pulse wave velocity and central blood pressure were assessed by the Sphygmo-Cor device (AtCor Medical West Ryde, Australia). Results: A significant improvement of W/L and of other indices of retinal artery structure was observed after treatment with lercanidipine alone, with a further improvement after treatment with lercanidipine + enalapril, whereas after treatment with lercanidipine + hydrochlorothiazide the improvement was no longer observed. A similar behaviour was observed for central SBP and DBP. Capillary density was increased only after treatment with lercanidipine + enalapril. Conclusion: Lercanidipine both in monotherapy and in combination with enalapril, was able to improve microvascular structure and to decrease central blood pressure, being thus a useful approach for both reducing blood pressure and improving vascular alterations in hypertension.


BioMed Research International | 2014

Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation

Michele Malagola; Cristina Skert; Giuseppina Ruggeri; Alessandro Turra; Rossella Ribolla; Valeria Cancelli; Federica Cattina; Elisa Alghisi; Simona Bernardi; Simone Perucca; Andrea Di Palma; Erika Borlenghi; Chiara Pagani; Giuseppe Rossi; Luigi Caimi; Domenico Russo

To evaluate if WT1 expression may predict relapse after allo-SCT, we analyzed WT1 levels on peripheral blood (PB) and bone marrow (BM) before and after allo-SCT in 24 AML patients with WT1 overexpression at diagnosis. Five copies of WT1/ABL × 104 from PB were identified as the threshold value that correlated with relapse after allo-SCT. The same correlation was not identified when WT1 expression was assessed from bone marrow (BM). Eight out of 11 (73%) patients with a pre-allo-SCT PB-WT1 ≥ 5 and 4/13 (31%) patients with a pre-allo-SCT PB-WT1 < 5 relapsed, respectively (P = 0.04). The incidence of relapse was higher in patients with PB-WT1 ≥ 5 measured after allo-SCT, at the 3rd (56% versus 38%; P = 0.43) and at the 6th month (71% versus 20%; P = 0.03). Patients with pretransplant PB-WT1 < 5 had significantly better 2-year OS and LFS than patients with a PB-WT1 ≥ 5 (81% versus 0% and 63% versus 20%) (P = 0.02). Our data suggest the usefulness of WT1 monitoring from PB to predict the relapse in allotransplanted AML patients and to modulate the intensity of conditioning and/or the posttransplant immunosuppression in an attempt to reduce the posttransplant relapse risk.


Scientific Reports | 2017

RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients

Marika Vezzoli; Antonella Ravaggi; Laura Zanotti; Rebecca Angelica Miscioscia; Eliana Bignotti; Monica Ragnoli; Angela Gambino; Giuseppina Ruggeri; Stefano Calza; Enrico Sartori; Franco Odicino

Some aspects of endometrial cancer (EC) preoperative work-up are still controversial, and debatable are the roles played by lymphadenectomy and radical surgery. Proper preoperative EC staging can help design a tailored surgical treatment, and this study aims to propose a new algorithm able to predict extrauterine disease diffusion. 293 EC patients were consecutively enrolled, and age, BMI, children’s number, menopausal status, contraception, hormone replacement therapy, hypertension, histological grading, clinical stage, and serum HE4 and CA125 values were preoperatively evaluated. In order to identify before surgery the most important variables able to classify EC patients based on FIGO stage, we adopted a new statistical approach consisting of two-steps: 1) Random Forest with its relative variable importance; 2) a novel algorithm able to select the most representative Regression Tree (RERT) from an ensemble method. RERT, built on the above mentioned variables, provided a sensitivity, specificity, NPV and PPV of 90%, 76%, 94% and 65% respectively, in predicting FIGO stage > I. Notably, RERT outperformed the prediction ability of HE4, CA125, Logistic Regression and single cross-validated Regression Tree. Such algorithm has great potential, since it better identifies the true early-stage patients, thus providing concrete support in the decisional process about therapeutic options to be performed.


Archive | 1987

Analytical Use of Antibodies Based on Specific Molecular Binding

A. Albertini; C. Iacobello; Giuseppina Ruggeri; Paolo Arosio

In the last few years the performance of analytical systems based on antibodies has improved enormously, due to the simplification of techniques, the development of non-isotopic tracers to follow the antigen-antibody reaction and the introduction of monoclonal antibodies with better defined specificity. An increasing number of fields in medicine are now interested in the development of immunoassays.


Clinical Chemistry | 2003

Identification of New Mutations of the HFE, Hepcidin, and Transferrin Receptor 2 Genes by Denaturing HPLC Analysis of Individuals with Biochemical Indications of Iron Overload

Giorgio Biasiotto; Silvana Belloli; Giuseppina Ruggeri; Isabella Zanella; Gianmario Gerardi; Marcella Corrado; Elena Gobbi; Alberto Albertini; Paolo Arosio


Gastroenterology | 1989

Immunohistochemical evidence for a lack of ferritin in duodenal absorptive epithelial cells in idiopathic hemochromatosis

Anna Ludovica Fracanzani; Silvia Fargion; Riccardo Romano; Alberto Piperno; Paolo Arosio; Giuseppina Ruggeri; G. Ronchi; Gemino Fiorelli


La Ricerca in Clinica E in Laboratorio | 1984

Evaluation of heart isoferritins in serum using specific monoclonal antibodies.

Ferruccio Cavanna; Giuseppina Ruggeri; Giorgio Chieregatti; Enzo Murador; Paolo Arosio; Alberto Albertini


Blood | 2006

An Analysis of the Incidence, Risk Factors and Prognosis of Acute Promyelocytic Leukemia Following Mitoxantrone Therapy in Patients Affected by Multiple Sclerosis.

Chiara Cattaneo; Erika Borlenghi; Cinzia Cordioli; Samantha Ferrari; Antonio Regazzoli; Giuseppina Ruggeri; Elena Gobbi; Maria Adele Capucci; Moira Micheletti; Ruggero Capra; Giuseppe Rossi

Collaboration


Dive into the Giuseppina Ruggeri's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Silvana Belloli

Vita-Salute San Raffaele University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge